Skip to content

← All developments

FDA Recalls · September 11, 2026 · Primary source

Centric Compounding Issues Nationwide Recall of Glutathione, Myer’s Cocktail, and Tri-Immune Boost Due to Elevated Endotoxin Levels

Score 50PRIMARYenforcementFDA

Summary

FDA issued a voluntary recall notice on September 9, 2026, for six lots of compounded injectable products, Glutathione 200mg/mL, Myer's Cocktail, and Tri-Immune Boost, distributed nationwide by Centric Compounding of Houston, Texas. The recall is triggered by elevated endotoxin levels in the Glutathione API used to compound the affected vials. The recall extends to the consumer level, meaning end users and patients are within the recall scope.

What this may mean

Compounding pharmacies sourcing Glutathione API face immediate product-withdrawal obligations at the consumer level for the six identified lots. The endotoxin finding implicates 503A and 503B compounding standards under FDA oversight and signals heightened scrutiny of injectable compounded products using this API.

Informational only. Not legal, medical, financial, or other professional advice. Always consult a qualified professional familiar with your specific facts before relying on any item.

Related items